Bicara TherapeuticsBCAX +0.76%12 Cash Ratio is 13.72 as of Mar. 2026, which is 7% below its 10-year median of 14.81. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,388 Biotechnology companies, Bicara Therapeutics ranks better than 86.74% on this metric.
Bicara Therapeutics has a Cash Ratio of 13.72. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Bicara Therapeutics's Cash Ratio or its related term are showing as below:
BCAX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.17 Med: 14.81 Max: 35.96
Current: 13.72
During the past 4 years, Bicara Therapeutics's highest Cash Ratio was 35.96. The lowest was 0.17. And the median was 14.81.
BCAX's Cash Ratio is ranked better than 86.74% of 1388
companies
in the Biotechnology industry
Industry Median: 2.93
vs BCAX: 13.72
Bicara Therapeutics (NAS:BCAX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Bicara Therapeutics Cash Ratio Related Terms
Bicara Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Bicara Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bicara Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicara Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Bicara Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicara Therapeutics (BCAX) has a Cash Ratio of 13.72 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Bicara Therapeutics and its competitors. This is near median its historical median of 14.81. Over the past decade, Bicara Therapeutics' Cash Ratio has ranged from 0.17 to 35.96. According to the industry distribution chart, Bicara Therapeutics ranks #184 out of 1388 companies in the Biotechnology industry, placing it in the top 13.3%.
Is Bicara Therapeutics' Cash Ratio too high?
Bicara Therapeutics' current Cash Ratio of 13.72 is near median its 10-year median of 14.81. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 35.96. The Biotechnology industry median Cash Ratio is 2.93. Bicara Therapeutics' value of 13.72 is 368.3% above this industry median. Based on the distribution chart, Bicara Therapeutics ranks #184 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Cash Ratio compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #184 out of 1388 companies for Cash Ratio. This places Bicara Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Bicara Therapeutics' value of 13.72 is 368.3% above this benchmark. Historically, Bicara Therapeutics' own Cash Ratio has ranged from 0.17 to 35.96 over the past decade. While the company's 10-year median is 14.81 vs. the industry median of 2.93, Bicara Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicara Therapeutics's current Cash Ratio of 13.72 is 368.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Bicara Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicara Therapeutics's current Cash Ratio is 13.72, which is near median its own 10-year median of 14.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Cash Ratio of 13.72. The current Cash Ratio is 13.72, which is near median its 10-year median of 14.81 and 368.3% above the Biotechnology industry median of 2.93. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Cash Ratio is 13.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score
Get the complete analysis for BCAX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCAX has been successfully added to your 
